The major histocompatibility complex class II (MHC-II) locus encodes a cluster of highly polymorphic genes HLA-DR, -DQ and -DP that are co-expressed in mature B lymphocytes. Two cell lines were established over 30 years ago from a patient diagnosed with acute lymphocytic leukemia. Laz221 represented the leukemic cells of the patient; whereas Laz388 represented the normal B cells of the patient. Although Laz388 expressed both HLA-DR and HLA-DQ surface and gene products, Laz221 expressed only HLA-DR genes. The discordant expression of HLA-DR and HLA-DQ genes was due to epigenetic silencing of the HLA-DQ region CCCTC transcription factor (CTCF)-binding insulators that separate the MHC-II sub-regions by DNA methylation. These epigenetic modifications resulted in the loss of binding of the insulator protein CTCF to the HLA-DQ flanking insulator regions and the MHC-II-specific transcription factors to the HLA-DQ promoter regions. These events led to the inability of the HLA-DQ promoter regions to interact with flanking insulators that control HLA-DQ expression. Inhibition of DNA methylation by treatment with 5 0 -deoxyazacytidine reversed each of these changes and restored expression of the HLA-DQ locus. These results highlight the consequence of disrupting an insulator within the MHC-II region and may be a normal developmental mechanism or one used by tumor cells to escape immune surveillance.
Introduction
The major histocompatibility complex class II (MHC-II) genes encode cell surface a/b heterodimeric glycoproteins that present foreign antigens to antigen-specific CD4 þ T lymphocytes in order to initiate, control and/or maintain adaptive immune responses. 1 There are three MHC-II isotypes HLA-DR, -DQ and -DP encoded within the MHC-II locus. This process is aided by two other MHC-II-associated molecules, HLA-DM and -DO, which are also a/b heterodimers with sequence and structural homology to MHC-II proteins. 2, 3 Although the levels of mRNA and protein from each of the above genes differ, all are typically coexpressed in a tissue-specific manner. MHC-II genes are expressed constitutively in B-lymphocytes, macrophages, dendritic cells and thymic epithelia, and can also be induced in most other cell types following exposure to interferon-g (reviewed in Ting and Trowsdale 4 ). The transcription of MHC-II genes is coordinated by a conserved group of transcriptional factors, regulatory factor X (RFX), cyclic adenosine monophosphate response element-binding protein and nuclear factor-Y, which bind to highly conserved, promoter-proximal sequences termed the X1, X2 and Y boxes, respectively. [4] [5] [6] The class II transactivator (CIITA), a non-DNA-binding transcription factor, is recruited to the DNA bound X and Y box transcription factors and mediates the interaction between cofactors, chromatin remodeling factors and general transcription machinery. 5, 7, 8 CIITA expression is limiting and is highly regulated. [9] [10] [11] In addition to the promoter proximal elements, distal elements contribute to the expression of the genes in this locus. [12] [13] [14] The MHC-II locus is punctuated by a series of CCCTC transcription factor (CTCF)-binding sites. 15 CTCF binding to its target DNA sequences is methylation sensitive, 16, 17 and CTCF has been shown to demarcate and insulate regions of regulatory activity within the genome by functioning as an enhancer blocker. 18 or by preventing the spread of heterochromatin into active genes. [19] [20] [21] CTCF has been proposed to function in part by forming the nexus of longrange chromatin loops. Recently, CTCF was found to be required for the expression of all MHC-II genes. 15, 22 The binding of CTCF to the insulator site between HLA-DR and HLA-DQ, termed XL9, results in the formation of longrange chromatin loops between XL9 and the promoter proximal regulatory X-Y box regions of the flanking genes, HLA-DRB1 and HLA-DQA1. This interaction was coincident with gene expression and dependent on CTCF and CIITA binding to their respective sites. 22 The depletion of CTCF by RNA interference, resulted in the loss of HLA-DRB1 and HLA-DQA1 gene expression. These studies predict that disruption of CTCF binding to one of the MHC-II insulator sites may have a significant consequence on MHC-II gene expression.
In 1978, Lazarus et al. 23 established the Laz221 cell line from a patient with acute lymphoblastic leukemia.
Laz221 cells were similar in phenotype to the acute lymphocytic leukemia cells of the patient and were considered to represent null cells at the time. Later Laz221 cells were determined to be most similar to a pre-B lymphocyte and were thought to arise from these cells. 24, 25 The cell line Laz388 was established from the same patient by transforming with Epstein-Barr virus 23, 26 and represented a normal peripheral B cell. One curious difference between the cells was that, although Laz388 expressed both HLA-DR and HLA-DQ proteins, Laz221 only expressed the HLA-DR proteins. 24, 25 Analysis of the cells showed that the HLA-DR genes were expressed in Laz221 but neither HLA-DQA or HLA-DQB was expressed. 24 Examination of the cis-regulatory elements by transfection of DNA reporter constructs into each of the cell lines and the use of electrophoretic mobility shift assays suggested that the HLA-DQB1 gene was regulated differently and that the Laz221 cell line was lacking a critical component. 24, 27 Because Laz221 expressed HLA-DR molecules at normal levels, this meant that each of the MHC-II-specific transcription factors RFX5, RFX-B, RFXAP and CIITA were present and fully active and that some other aspect of the system was defective. On discovery of XL9 and its role in HLA-DRB1 and HLA-DQA1 transcription, we hypothesized that the differential expression of the HLA-DQ locus in Laz221 might involve the use of XL9. We found that the region between and including the two insulators XL9 and C2 was hypermethylated in Laz221 but not Laz388 cells. DNA methylation resulted in the loss of CTCF binding and long distance interactions between the XL9 and MHC-II gene promoters. Critically, treatment with 5 0 -deoxyazacytadine (5-azaC) reverted each of the molecular defects in Laz221 cells, resulting in the reexpression of the HLA-DQ genes. Thus, these data point to DNA methylation of an MHC-II sub-region and insulator as a potential mechanism by which cells may attempt to avoid detection by the immune system through the loss of an MHC-II isotype.
Results

CTCF does not bind to the MHC insulators that surround the HLA-DQ sub-region in Laz221 cells
Previous analyses demonstrated differential expression of HLA-DR and HLA-DQ surface protein levels between the Laz221 and Laz388 cell lines. 24, 25 This data is recapitulated in Figure 1a , which shows two distinct expression profiles for these cells. Previous work also showed that HLA-DQB mRNA was not expressed in Laz221. 24 Confirmation of that result showed that compared with Laz388, Laz221 cells had extremely low levels of HLA-DQB1 mRNA. Additionally in Laz221 cells, HLA-DQA1 mRNA levels were very low, suggesting that the cause of expression may be related to the HLA-DQ locus. Similar levels of HLA-DRB1 transcripts were observed between the cell lines ( Figure 1b) . Southern hybridization experiments showed that HLA-DRB1 and HLA-DQB1 were similar in both cell lines, indicating no major deletion in the genes. 24 Since the previous analyses of these cell lines, we now know that the RFX complex (RFX5, RFX-B and RFXAP) and CIITA are specific to and required for the expression of all MHC-II genes. 4 The finding that HLA-DR is expressed on the surface and that HLA-DRB1 mRNA is present in Laz221 cells argues that the RFX subunits, CIITA, and other necessary transcription factors for MHC-II transcription are fully functional in Laz221 cells. Our recent discovery that HLA-DQA1 used the XL9 insulator as a distal regulator of HLA-DQA1 expression, 22 led us to examine if XL9 was mutated in Laz221 cells. However, DNA sequencing of genomic clones isolated from Laz221 and Laz388 showed identical sequences (data not shown). We also tested whether CTCF, the insulator factor at XL9 that is responsible for its MHC-II regulatory activity, was normally expressed Laz221 cells. Western blotting of both Laz388 and Laz221 revealed that the overall levels of CTCF are similar with Laz221 expressing slightly more CTCF than Laz388 cells (Figure 2a) .
In addition to XL9, another CTCF-binding insulator termed C2, was recently identified that lies between HLA-DQB1 and the pseudogene HLA-DQA2 (Figure 2b and HLA-DQB1. 15 Thus, to determine whether CTCF binding to Laz221 was similar to that in Laz388, chromatin immunoprecipitation (ChIP) assays were performed at XL9 and C2 (Figure 2b ). Although CTCF bound to XL9 and C2 in Laz388 cells, it did not bind to these sites in Laz221 cells. The binding of CTCF was specific as shown by the nonspecific DNA and antibody controls presented (Figure 2b ). This suggested that a potential cause for the lack of HLA-DQ expression could be do to the inability to bind CTCF at XL9 and C2.
XL9 and the HLA-DQ region are hypermethylated in Laz221 cells DNA methylation is a heritable mark that can result in reducing the accessibility of DNA to transcription factors by controlling the local chromatin structure. DNA methylation is also known to prevent CTCF binding to its target sequences; 16, 17, 31 suggesting a mechanism by which CTCF binding may be abrogated in Laz221 cells. To determine whether DNA methylation may have a role in the differential expression of the HLA-DQ genes, methyl-DNA immune precipitation assays (MeDIP) were conducted across the HLA-DQ sub-region. 29 In MeDIP, DNA is fragmented by sonication to produce fragments of 600-1000 bp in length. A methylcytosine-specific antibody is used to immunoprecipitate the DNA before to analysis by real-time PCR. The MeDIP technique circumvents the sequence bias that is present in the methylation sensitive restriction digestion technologies and can be rapidly applied across a region. A series of amplicons from just upstream of XL9 to downstream of C2 was designed and used to assess the locus. The results showed that the sequences surrounding XL9 were highly enriched for cytosine methylation in Laz221 cells but showed no methylation in Laz388 ( Figure 3 ). In addition, each of the promoter regions surrounding the HLA-DQA1 and HLA-DQB1 genes were also methylated in Laz221 cells but not in Laz388. Lastly, the C2 insulator was also hypermethylated in Laz221 cells compared with Laz388. In contrast, the HLA-DRB1 proximal promoter region and that of a CpG island in the b-actin gene showed no enrichment for methylcytosine containing DNA. Intriguingly, the sequences represented by amplicons C2a and C2b, which lie outside of the XL9-C2 defined HLA-DQ region showed no cytosine DNA methylation, suggesting that C2 was the boundary of this epigenetic mark. Sequences XL9a and XL9b, which represent random regions also outside of the XL9-C2 domain, exhibited DNA methylation irrespective of the cell line, suggesting that methylation of these sequences is normally associated with this intergenic region. Although the number of methylated cytosines correlates with signal strength in the MeDIP assay, the data DNA methylation silences HLA-DQ expression P Majumder and JM Boss collected were not simply because of the number of potential CpGs within a region, as XL9 has fewer CpG sites within the 500 bp surrounding DNA than HLA-DQA1 or HLA-DQB1 (Table 1) . In addition to DNA methylation, chromatin accessibility is modulated through a variety of histone modifications that serve to recruit heterochromatinmodulating factors. One such factor is heterochromatin protein-1 (HP-1), which recognizes chromatin that contains histone H3K9me3 post-translational modifications. 32 To determine whether the regions bearing DNA methylation carried heterochromatin modifications, ChIP assays were carried out for HP-1 and H3K9me3 (Figure 4) . The results showed that the repressive histone modification and HP-1 were present at XL9 chromatin but not at the proximal promoters in Laz221 cells. Neither the mark nor HP-1 was found at these sites in Laz388 cells. Together, these data demonstrate that the HLA-DQ sub-region is hypermethylated in Laz221 cells and that the XL9 insulator region is packaged in a repressive chromatin structure that would be predicted to silence its function.
The HLA-DQ proximal promoter regions do not bind RFX and CIITA The DNA methylation patterns over the proximal promoter regions of the HLA-DQA1 and HLA-DQB1 genes suggest that RFX and CIITA may not be able to bind to their respective sequences. To test this hypothesis, the in vivo occupancies of RFX5 and CIITA to the HLA-DRB1 and HLA-DQA1 in Laz221 and Laz388 cells were determined by ChIP. As expected RFX5 and CIITA bound to the promoter proximal regions of HLA-DRB1 in both cell lines and to HLA-DQA1 and HLA-DRB1 in Laz388. However, RFX5 and CIITA did not bind to the promoter proximal region of HLA-DQA1 or HLA-DQB1 ( Figure 5 ). This suggests that DNA methylation may prevent the assembly of the active proximal promoter regulatory regions and actions of XL9 and C2.
Inhibition of DNA methyltransferase reverses the differential expression of HLA-DQ genes in Laz221 cells To determine whether DNA methylation was responsible for the Laz221 phenotype, Laz221 cells were treated for 2 days with 5-azaC, an inhibitor of the maintenance DNA methyltransferase DMNT1. [33] [34] [35] Total RNA was isolated and analyzed for the expression of HLA-DRB1, HLA-DQA1 and HLA-DQB1 mRNA levels (Figure 6a ). Although 5-azaC treatment increased the levels of HLA-DRB1 by three-to fourfold (data not shown), the levels of HLA-DQA1 were increased by 40-fold and levels of HLA-DQB1 were increased by 7.5-fold over the untreated cultures. Moreover, 5-azaC treatment also resulted in the ability of RFX5, CIITA and CTCF to bind their target sites in Laz221 cells (Figure 6b) .
XL9 functions by interacting directly with the proximal promoter regions of the HLA-DRB1 and HLA-DQA1 genes.
22 C2 was found to interact with HLA-DQA1 and HLA-DQB1. 15 Disruption of these interactions by depleting CTCF results in a loss of expression from these promoters. 22 Thus, it was of interest to determine if the DNA methylation played a role in these interactions. Interactions between distal elements can be observed using the chromatin conformation capture (3C) assay. 22, 30 The formation of a 3C product provides a measure of the spatial proximity of the elements in question compared with a randomly selected element. In this study, the ability of XL9 and C2 to interact with the promoter proximal restriction fragments of HLA-DRB1 and HLA-DQA1 was compared with random sequences located within the locus. Previous analyses have characterized DNA methylation silences HLA-DQ expression P Majumder and JM Boss these elements and the controls required to demonstrate that the system was operational. 15, 22 In Laz388, 3C products were formed between XL9 and HLA-DRB1 and HLA-DQA1, but not with the control fragments P12 and P19 (Figure 7b ). In Laz221, 3C products were not observed between XL9 and either promoter proximal restriction fragment. Similarly, C2 interacted with HLA-DQA1 and HLA-DQB1 in Laz388 but not in Laz221 (Figure 7c ). These results indicate that the insulator regions were not active in modulating MHC-II activity in Laz221 cells. The inability to form 3C products in Laz221 was not due to restriction site accessibility, as the conditions used still allowed enzyme access to the sites of the isolated chromatin (Supplemental Figure 1) . Treatment of Laz221 cells with 5-azaC resulted in the formation of the XL9-HLA-DQA1, C2-HLA-DQA1 and C2-HLA-DQB1 3C interactions at comparable frequencies with those observed in Laz388. No interactions were observed with the control fragments following 5-azaC treatment. Thus, DNA methylation in this system also blocks XL9 and C2 function.
Discussion
The pre-B-cell leukemia-derived cell line Laz221 was isolated from the patient who was diagnosed with acute lymphocytic leukemia in 1978. 23 A normal B cell line Laz388 was also established from the same patient. 26 Nearly, a decade later it was found that these cells differentially expressed MHC-II genes. 24, 25 At that time, the differential HLA-DQ expression was postulated to be due to a deficiency in Laz221 that was specific to the expression of the HLA-DQB gene. 24, 27 With the current understanding that all MHC-II isotypes are coordinately regulated by a common set of factors 4, 10 and the recent identification of insulator elements that contribute to the expression of the locus, we sought to reinvestigate this cell line and its autologous partner Laz388 to determine the molecular basis of the differential expression of the HLA-DQ genes. The results showed that the HLA-DQ sub-region of the MHC was hypermethylated in Laz221 compared with Laz388 cells. DNA hypermethylation disabled three separate mechanistic events necessary for the expression of an MHC-II gene. Importantly, inhibition of DNA hypermethylation within the HLA-DQ subregion restored HLA-DQ gene expression and each of the biochemical pathways associated with HLA-DQ gene regulation.
The first of these events was that DNA methylation of the HLA-DQA1 and HLA-DQB1 proximal promoter X-Y box sequences prevented the assembly of the RFX and CIITA enhanceosome complex that is required for MHC-II gene expression. 7, 10 Without the binding of these factors to the proximal promoter regions, the transcription of these genes could not occur. Thus, in a genespecific manner, the DNA methylation of the proximal promoters created a situation that mimicked the phenotype of an RFX-subunit-deficient bare lymphocyte patient's B cells, 36, 37 in which the critical factors failed to assemble. 38 The observations that RFX and CIITA were In contrast to this, high levels of RFX5 and CIITA were detected at the same region in Laz388 cells. High levels of RFX5 and CIITA were observed on HLA-DRB1 promoter where no significant difference was found in both cell lines. XL9 and C2 do not bind RFX or CIITA. These data were derived from three independent chromatin preparations. DNA methylation silences HLA-DQ expression P Majumder and JM Boss bound at HLA-DRB1 in Laz221 cells, and that 5-azaC reverted the binding of these factors to HLA-DQA1, provides evidence that the chromatin samples and assay system used in these ChIP experiments are sufficiently controlled.
Second, DNA methylation of XL9 and C2 resulted in chromatin that could not bind CTCF. This effectively removed CTCF from being able to participate in the activation of the neighboring MHC-II genes. A surprise was that in addition to XL9 and C2 being hypermethylated, we found that the XL9 region contained high levels of the repressive histone modification H3K9me3 and was associated with HP-1, the heterochromatin protein that recognizes this mark. 39, 40 This suggests the possibility that this region is packaged in a heterochromatic state and that the histone modification is having a role in the silencing of the region. The heterochromatin mark did not spread to the HLA-DQ gene promoter regions, suggesting that it was highly localized. Third, the loss of both CIITA and CTCF binding to their target sites had the net effect of eliminating the ability of these sites to interact with each other. Thus, the long-distance chromatin loops that form between the CTCF sites and the HLA-DQ genes did not occur. In addition to XL9 and C2, the MHC-II region has eight other CTCF sites in the locus. 15 These CTCF sites interact with each other, as well as the neighboring MHC-II gene promoters. Although large in scale (B150 to 200 kb), the frequency of interactions is dependent on the distance between the sites. CTCF binding is required for these sites to interact with each other and CIITA is required for additional interactions between the CTCF sites and MHC-II gene promoter regions. 15 Thus, the DNA methylation and heterochromatin events at the two insulators that border the HLA-DQ sub-region, disrupt the normal architecture of the locus.
The loss of CTCF binding to XL9 raises the issue of how HLA-DRB1 can be expressed as its closest CTCF site is silenced. In addition to XL9, HLA-DRB1 interacts with the CTCF site that is upstream of the HLA-DRA gene, termed C1. 15 Thus, it has a choice of which site it can use. The data presented here suggests that the loss of one available CTCF site does not prevent expression of an MHC-II gene if another site can be used. Thus, the system has redundancies built in. Intriguingly, in Raji cells, HLA-DQA1 interacts with only XL9 and C2, 15 for which both of these sites are inactive in Laz221.
Transcriptional insulators are often complex elements that in addition to having the ability to block an enhancer from activating a downstream target gene, they can also prevent the encroachment of heterochromatin into a region. 41 This latter activity is attributed to barrier or boundary function of the elements. More recently the activities associated with the b-globin HS4 insulator, which exhibited all of these activities, have been dissected and individual functions, enhancer blocking versus boundary function, were found to be the result of separate definable elements. 42 This raises the question as to whether the CTCF-binding sites within the MHC-II locus have multiple activities. XL9 mediates strong enhancer blocking activity, 12 however, barrier activity was not assessed for XL9 or any of the other MHC-II CTCF elements. In the results presented here, the differential DNA hypermethylation did not seem to spread outside of the HLA-DQ region. Because CTCF cannot bind to its sites, it is reasonable to postulate that it does not contribute to such an activity. This assessment is consistent with the fact that the zinc-finger protein VEZF1 was found to be responsible for preventing the spread of heterochromatin in the HS4 insulator. 42 DNA methylation of MHC-II genes has been observed previously and correlated with silencing of the locus. [43] [44] [45] In these studies, the HLA-DR region was methylated as determined by Southern blots and methylation sensitive restriction enzymes, and HLA-DQ genes were not assessed. In other studies, differential HLA-DR and - (c) The 3C assays in which C2 served as the anchor primer to test interactions between the C2 restriction fragment and other restriction fragments containing either the HLA-DQA1 or -DQB1 promoters. The data from three independent 3C chromatin preparations was averaged and plotted with respect to the relative amount of 3C product. Control restriction fragments are indicated as the P12, P19, CL4 and CL5 primer positions.
DQ expression was observed, but the molecular basis was not established. 25, [46] [47] [48] Thus, there is a long history of methylation as a mechanism to control MHC-II expression. Because MHC-II gene products are typically coexpressed, this raises the question of how both alleles received the same epigenetic mark to silence the HLA-DQ sub-region. We pose that there are two possibilities. The first is that the Laz221 leukemic line may represent a developmental snap shot of B-cell development. In such a scenario, the HLA-DQ region would be normally silenced and activated at a later developmental cell stage. Several reports support this notion. HLA-DQ expression was reported to lag behind HLA-DR and HLA-DP during early fetal development. 46 In addition hematopoegenic progenitors were found to express HLA-DR and HLA-DP but not HLA-DQ. 48 Lastly, in a similar vein, it is possible that the entire locus is controlled by DNA methylation events. In embryonic and pluripotent stem cells, HLA-DRA was not expressed or inducible by interferon-g, unless the cells were pretreated with 5-azaC. 49 Bisulfite sequencing showed that the HLA-DRA locus was hypermethylated in these cells.
A second possibility is that a strong selection event led to the silencing of both HLA-DQ alleles and that DNA methylation was the successful strategy to silence the loci. In diffuse large B-cell lymphoma, MHC-II expression is often lost through a variety of mechanisms some of which include the reduction of CIITA expression but others remain unknown. [50] [51] [52] [53] In these cancers, the loss of MHC-II expression is associated with a poorer prognosis than those lymphomas expressing MHC-II. 51 Fewer tumor infiltrating CD8 T cells were associated with MHC-IInegative diffuse large B-cell lymphomas than MHC-II positive, suggesting a connection between MHC-II-positive cells and tumor surveillance mechanisms. The DNA methylation events found associated with Laz221 cells represent one mechanism by which MHC-II genes and a particular isotype can be silenced; thus, it would not be surprising if other lymphomas/leukemias were ultimately identified that displayed MHC-II silencing events that occurred through a DNA methylation and/or the loss of an MHC-II-specific insulator function.
Materials and methods
Cell culture
The Laz221 and Laz388 cell lines 23, 26 originally derived from the peripheral blood of a patient with acute lymphocytic leukemia. These two cell lines were obtained from Dr G Nepom (Benaroya Institute, WA, USA) and were grown in RPMI-HEPES supplemented with 10% fetal bovine serum (Hyclone Inc., Logan, UT, USA), 2 mM Lglutamine, penicillin/streptomycin 50 U ml À1 and 1 mM sodium pyruvate. Laz221 cells were grown in the absence or presence of 5 mM 5-azaC (Sigma-Aldrich, Cat#A2385). The 5-azaC was added at 8 h intervals to the growth media for 2 days.
Flow cytometry
Cells were harvested, washed twice with cold phosphate-buffered saline and incubated with phycoerythrin-conjugated anti-human HLA-DR antibody or unconjugated anti-human HLA-DQ antibody (BD bioscience Pharmingen, San Diego, CA, USA) followed by staining with a phycoerythrin-conjugated anti-mouse immunoglobulin G secondary antibody (Southern Biotech, Birmingham, AL, USA). A FACScalibur (BD Biosciences, San Jose, CA, USA) flow cytometer was used to analyze the expression level of human MHC-II surface expression. MHC-II-positive cells were visualized using the FL2 channel. Control stained samples were processed in parallel using only the secondary antibodies indicated in the figures.
Quantitative RT-PCR Total RNA was isolated from Laz388 and Laz221 cells using the RNeasy RNA isolation kit (Qiagen, Valencia, CA, USA) according to the company's protocol. The complementary DNA synthesis was performed using Superscript II reverse transcriptase (Invitrogen Inc., Carlsbad, CA, USA) with 2 mg of total RNA in a volume of 20 ml in PCR II buffer containing 5 mM MgCl 2 (Applied Biosystems, Foster City, CA, USA). After reverse transcription, sample volumes were increased to 200 ml with TE buffer (10 mM Tris, 1 mM EDTA, pH 7.5) and 3 ml of the complementary DNA was used for quantitative PCR assays. GAPDH primers were used in each of the experiments to normalize the data between samples. PCR primers are listed in Supplementary Table  1 . The data presented represent the average of three independent experiments and are plotted with their standard deviation. The student's t-test was used to determine statistical significance.
ChIP assay
ChIP assays were performed as described previously. 8, 12, 14, 22 For immunoprecipitations, 5-10 mg of anti-CTCF (Upstate Antibodies, Lake Placid, NY, USA (Now Millipore, Inc.), Cat no. 06-917), anti-RFX5, 28 anti-CIITA 8 or anti-T-cell receptor (nonspecific control) antibodies were used. Protein A beads (60 ml) were used to isolate the chromatin-antibody bound complexes. After extensive washing, the immunoprecipitated chromatin was eluted in 1% SDS and incubated overnight at 65 1C to reverse the crosslinks. The DNA was purified and used as a template in real-time PCR analyses. Immunoprecipitated DNA samples were quantitated by real-time PCR using a five-point genomic DNA standard curve and an I-cycler (Biorad Laboratories Inc., Hercules, CA, USA) as previously described. 22 SYBR-Green incorporation quantitative PCR reactions contained 5% dimethyl sulfoxide, 1 Â SYBR-Green (Bio Whittaker Molecular Applications), 0.04% gelatin, 0.3% Tween 20, 50 mM KCl and 20 mM Tris (pH 8.3), 3 mM MgCl 2 , 0.2 mM deoxyribonucleotide triphosphate and 100 nM of each primer. Primer sequences are listed in Supplemental Table 1 . All ChIP experiments were performed at least three times from independent preparations of chromatin. The data were averaged and plotted as a percentage of input chromatin with standard error bars as indicated.
Quantitative MeDIP assay
MeDIP assays were performed as described by Weber et al. 29 with the following modifications. Genomic DNAs were purified from Laz388 and Laz221 cells using DNAzol genomic DNA isolation reagent as described by the manufacturer (Molecular Research Center Inc., Cat no. DN-127). Genomic DNAs were sonicated in TE buffer to produce random fragments of about 600 bp. Fragmented DNA (4 mg) for each experimental sample was denatured and incubated for 2 h with 5 mg of anti-5-methylcytidine antibodies (Eurogenetec Inc.; Cat no. BI-MECY-0100) in a final volume of 500 ml of IP buffer (10 mM sodium phosphate (pH 7.0), 140 mM NaCl, 0.05% Triton X-100). A volume of 30 ml of Dynabeads (M-280 sheep antibody to mouse immunoglobulin G; Dynal Biotech Inc., Auburn, CA, USA) were used to isolate the 5-methycytidine bound DNA complexes. After extensive washing and treating with proteinase K, the immunoprecipitated DNA was extracted with phenol-chloroform, and recovered by ethanol precipitation. To quantitate the samples, real-time PCR was carried out with input and the immunoprecipitated DNAs as described in the above section for ChIP assays.
Quantitative 3C assay The 3C assays 30 were performed with modifications described previously. 22, 30 In this study, 1 Â 10 7 cells were isolated, crosslinked with formaldehyde to a final concentration of 1% for 10 min at room temperature and glycine was added to 125 mM to stop the crosslinking reaction. Nuclei were purified and digested overnight with EcoRI at 37 1C. Following heat inactivation of the enzyme, the samples were diluted B40:1 and then ligated with T4 DNA ligase. The DNA was purified and then used as a substrate for real-time PCR using the primers described in Majumder et al. 22 and shown in Supplemental Table 1 . All restriction sites assessed by 3C were equally accessible to restriction enzyme digestion as determined by PCR amplification across the sites following digestion. Standard curve templates for the 3C products were generated in vitro by restriction enzyme cleaving and religating the bacterial artificial chromosome RP11-257P24 (purchased from Children's Hospital Oakland Research Institute), which encodes the HLA-DRB1 and HLA-DQA1 sub-region and includes XL9 and C2. All primer combinations are listed in Supplemental Table 1 , and were tested previously 22 had a 490% PCR efficiency, and produce a single amplicon on cleaved/ religated bacterial artificial chromosome DNA. Data are presented as crosslinked frequency and represent an average derived from three independent biological replicates. Standard error is provided for the dataset. Student's t-tests were used to determine if observed differences were significant.
